Serum anti-Mullerian hormone throughout the human menstrual cycle

Marca, Antonio La; Stabile, Gaspare; Artenisio, Alfredo Carducci; Volpe, Annibale

doi:10.1093/humrep/del291

Cited by 466 publications

(301 citation statements)

References 23 publications

Supporting

Mentioning

256

Contrasting

Unclassified

Order By: Relevance

“…However, multiple regression analysis confirmed no correlation between AMH and FSH serum levels in each group, in agreement with previous observation in PCOS women Pigny et al 2003]. It was reported that serum AMH levels did not significantly change along with serum FSH levels that fluctuate throughout the menstrual cycle [La Marca et al 2004;La Marca et al 2006]. FSH either produced endogenously or administered did not appear to exert an effect on serum AMH levels when only one dominant follicle emerged [van Rooij et al 2002;Wachs et al 2007].…”

Section: Discussionsupporting

confidence: 89%

“…It seems that the high levels of AMH observed in PCO women in the late follicular phase (day of HCG administration) is not the reason for follicular arrest (the disruption of follicular development and maturation), whereas it predicts an excessive number of small antral follicles in PCO women which were not detected by ultrasound on the day of HCG administration, compared to control women. It has been observed that serum AMH levels remain rather constant in early and late follicular phases of a natural cycle [La Marca et al 2004;La Marca et al 2006;van Houten et al 2010], indicating that serum AMH levels might not influence follicular maturation. It appears that serum AMH levels at various stages of a natural or stimulated cycle are positively correlated with the numbers of small antral follicles in the ovary.…”

Section: Discussionmentioning

confidence: 99%

“…AMH, also known as Müllerian inhibitory substance (MIS), is primarily produced by granulosa cells of secondary, preantral, and small antral follicles [Baarends et al 1995;Weenen et al 2004]. AMH has been proposed as a marker of ovarian reserve [La Marca et al 2006;van Rooij et al 2002].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome

Hua

et al. 2014

Systems Biology in Reproductive Medicine

View full text Add to dashboard Cite

(2015) The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome, Systems Biology in Reproductive Medicine, 61:2, 103-109, DOI: 10.3109/19396368.2014.973123 To link to this article: https://doi.org/10. 3109/19396368.2014 AbstractThe aim of this study was to ascertain whether higher levels of serum anti-Mü llerian hormone (AMH) are associated with the ovarian follicular arrest in women with polycystic ovary syndrome (PCOS). This prospective study compared AMH levels between serum and dominant follicular fluid (FF) in ovulatory polycystic ovary (PCO) women and anovulatory (menstrual cycle !60 days.) PCOS women. All 102 women provided a baseline hormone profile and underwent controlled ovarian hyperstimulation (COH). The anovulatory PCO women had a similar body mass index (BMI), antral follicle count (AFC), and baseline serum AMH levels as the ovulatory PCO women except that their median luteinizing hormone (LH; 10.0 mIU/ml), testosterone (T) (0.61 ng/l), and androstenedione (A) (3.47 ng/l) levels were significantly higher than ovulatory PCO women (4.9 mIU/m; 0.43 ng/l and 2.09 ng/l, respectively). The ovarian response to gonadotropin stimulation during COH including serum AMH on the day of HCG administration and dominant FF AMH at 36 hours after HCG administration, total follicle stimulating hormone (FSH) dose administrated, peak E 2 , (estrogen) levels and number of occytes retrieved were all similar between women with anovulatory and ovulatory PCO. Using multiple regression analysis it was found that an important independent determinant affecting AMH was AFC, as opposed to LH and T. Logistic regression analysis showed that the two most important factors affecting ovulation were serum LH and T, whereas serum AMH and AFC were not selected for inclusion in the model. The reduction in AMH during COH occurs as a consequence of dominant follicles with a corresponding reduction in small antral follicle number. Elevated serum AMH levels in PCO women seem to be related only to follicular excess and not follicular arrest.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome

Hua

et al. 2014

Systems Biology in Reproductive Medicine

View full text Add to dashboard Cite

show abstract

“…Concerning the field of reproductive medicine, extremely interesting new data on the possible clinical application of AMH measurement in the prediction of quantitative and qualitative ovarian response in ART have been published in the last few years, since AMH exhibits a relatively stable expression throughout the menstrual cycle [17]. This suggests that AMH is an attractive determinant of ovarian activity.…”

mentioning

confidence: 99%

Single nucleotide polymorphisms in the Anti-Müllerian hormone (AMH Ile49Ser) and Anti-Müllerian hormone type II receptor (AMHRII −482 A>G) as genetic markers in assisted reproduction technology

Karagiorga

Partsinevelos

Mavrogianni

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The aim of the study was to evaluate whether the presence Antimullerian hormone (AMH) and Antimullerian hormone type II receptor (AMHRII) single nucleotide polymorphisms (SNPs) Ile 49 Ser and -482A>G respectively are related to the assisted reproduction outcome. Methods A prospective cross-sectional observational study was conducted in order to assess the distribution of AMH and AMHRII SNPs in two cohorts, one of healthy women (N=100) and the control group and the IVF/ICSI group (N=151) consisted of women undergoing IVF/ICSI treatment for infertility. Furthermore, a prospective longitudinal observational study was performed on the latter group to assess possible associations of these SNPs with patients' characteristics and controlled ovarian stimulation (COS) and pregnancy outcome. Results Among non-carriers of the AMH (Ile 49 Ser) polymorphism, basal FSH levels were lower in those with more than two of previous IVF attempts and fertilization rate was statistically higher in those with peak serum E2 levels below 1500 pg/ml, whereas among non-carriers of the AMHRII (−482 A>G) polymorphism, number of follicles was higher in those with more than two previous IVF attempts and total dose of gonadotropins was lower in those with peak serum E2 levels above 1500 pg/ml. Conclusions There was evidence that in specific subgroups of women undergoing IVF/ICSI, AMH and AMHRII SNPs may be related to patients' characteristics and controlled ovarian stimulation and pregnancy outcome and thus may provide a means for the prediction of ovarian response in specific subgroups of women entering an IVF/ICSI program.

show abstract

“…This was in part derived from studies that demonstrated minimal variation of AMH levels throughout the menstrual cycle. As AMH production has declined when follicles are selected for dominance, cyclic variation is thought to be minimal enough that measurement can be performed at any timepoint in the cycle [12]. However, more recent evidence indicates that AMH levels may fluctuate more than previously thought, with higher levels in the follicular phase compared to the luteal phase [13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHH

Chan

Liu

2014

J Assist Reprod Genet

View full text Add to dashboard Cite

Objective Serum anti-mullerian hormone (AMH) has been proposed as a useful marker of ovarian reserve that is cycleindependent and predictive of outcome in assisted reproduction cycles. However, there is evidence that AMH production is gonadotropin-dependent, and that under the influence of FSH, growing follicles contribute to circulating AMH levels. Therefore, AMH testing may not be universally reflective of the primordial follicle pool in certain conditions. We demonstrate that in patients with idiopathic hypogonadotropic hypogonadism (IHH) and deficient gonadotropin production, AMH and antral follicle count (AFC) may not be reliable markers of ovarian reserve. Design Case report. Setting Fertility clinic at a tertiary academic hospital. Patient A 30-year-old nulligravid patient with IHH who presented for fertility treatment with low FSH (0.3 IU/L), LH (0.1 IU/L), estradiol (77 pmol/L) and AMH levels (0.65 pmol/L), and an unmeasurable AFC. Intervention A three-month course of priming with oral micronized 17β-estradiol, followed by daily injections of human menopausal gonadotropins (hMG). Main outcome measure AMH level and follicular development.

show abstract

Serum anti-Mullerian hormone throughout the human menstrual cycle

Abstract: In this study, we demonstrated that serum AMH levels do not change significantly throughout the menstrual cycle. Hence, AMH exhibits a relatively stable expression during the menstrual cycle, making it an attractive determinant of ovarian activity.

Cited by 466 publications

References 23 publications

The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome

The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome

Single nucleotide polymorphisms in the Anti-Müllerian hormone (AMH Ile49Ser) and Anti-Müllerian hormone type II receptor (AMHRII −482 A>G) as genetic markers in assisted reproduction technology

Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHH

Contact Info

Product

Resources

About